Streetbeat News

Price Targets

AVB

JP Morgan analyst Anthony Paolone maintains an Underweight rating on AvalonBay Communities (NYSE:AVB) and raises the price target from $188 to $201.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 2:32 pm

PANW

Loop Capital analyst Yun Kim maintains a 'Buy' rating on Palo Alto Networks (NASDAQ:PANW) and raises the price target from $240 to $280.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 2:30 pm

DIS

Truist Securities analyst Matthew Thornton has reiterated a 'Buy' rating on Walt Disney (NYSE:DIS) and maintained a price target of $105.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 2:14 pm

PSTL

Truist Securities analyst Ki Bin Kim has reiterated a 'Hold' rating on Postal Realty Trust (NYSE:PSTL) and maintained a price target of $16.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 2:13 pm

IAC

Truist Securities analyst Youssef Squali has reiterated a 'Buy' rating on IAC (NASDAQ:IAC) and maintained a price target of $84.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 2:13 pm

BRX

Truist Securities analyst Ki Bin Kim has reiterated a 'Buy' rating on Brixmor Property Group (NYSE:BRX) and maintained a price target of $25.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 2:12 pm

MNOV

Zacks Small-Cap Research has set a $26 price valuation for MediciNova, a biopharmaceutical company. The valuation is highly dependent on the continued clinical success of the company's assets and will be adjusted based on future clinical results.

Portfolio Pulse from Happy Mohamed

August 21, 2023 | 2:12 pm

ANGI

Truist Securities analyst Youssef Squali has reiterated a 'Buy' rating on Angi (NASDAQ:ANGI) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 2:12 pm

REGN

Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Regeneron Pharmaceuticals and raised the price target from $875 to $980.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 2:11 pm

EL

Wells Fargo analyst Christopher Carey has maintained an Overweight rating on Estee Lauder Cos (NYSE:EL) but lowered the price target from $215 to $200.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 2:07 pm